Body, Jean-Jacques <br/><br/>
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Feb 2006 
 - 1221-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-05-1933  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--administration & dosage<br/>Area Under Curve<br/>Bone Neoplasms--prevention & control<br/>Bone and Bones--drug effects<br/>Breast Neoplasms--drug therapy<br/>Carrier Proteins--antagonists & inhibitors<br/>Collagen--blood<br/>Collagen Type I<br/>Creatinine--urine<br/>Denosumab<br/>Diphosphonates--administration & dosage<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Injections, Intravenous<br/>Injections, Subcutaneous<br/>Male<br/>Membrane Glycoproteins--antagonists & inhibitors<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Pamidronate<br/>Peptides--blood<br/>RANK Ligand<br/>Receptor Activator of Nuclear Factor-kappa B<br/>Time Factors<br/>Treatment Outcome